Search

Benzhydrocodone

[A182177] Benzhydrocodone is indicated for use in the short-term management of pain. … Benzhydrocodone is a benzylic prodrug of hydrocodone.[L4894] It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse.

Telotristat ethyl

[A252937] Serotonin is metabolized in the urinary metabolite 5-hydroxy indole acetic acid (u5-HIAA), and high levels of u5-HIAA is associated with poor survival outcome in patients with NET. … Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo.

Onametostat

Onametostat is a small molecule drug. The usage of the INN stem '-metostat' in the name indicates that Onametostat is a histone N-methyltransferase inhibitor. … Onametostat is under investigation in clinical trial NCT06788509 (A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring).

Gamcemetinib

Gamcemetinib is a small molecule drug. The usage of the INN stem '-tinib' in the name indicates that Gamcemetinib is a tyrosine kinase inhibitor. … Gamcemetinib is under investigation in clinical trial NCT04947579 (A Study of CC-99677 in Participants With Active Ankylosing Spondylitis).

Margetuximab

Of the various subtypes of breast cancer, HER2-positive breast cancer is characterized by _ERBB2_ overexpression, a higher grade, a more aggressive phenotype, and a worse prognosis compared to HER2-negative … [A225756] Margetuximab (formerly MGAH22) is an Fc-engineered human/mouse chimeric anti-HER2 IgG1κ monoclonal antibody derived from the same mouse 4D5 clone that [trastuzumab] is derived from and is

Ruxolitinib

Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. … [L31958] The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo.[L39125] It is being investigated for other inflammatory skin conditions.

Diloxanide furoate

Coagulation factor X human

Inherited factor X deficiency is a rare autosomal recessive bleeding disorder that is estimated to occur in 1:1 000 000 individuals up to 1:500 carriers [A31471]. … However its use is limited in the perioperative setting for the management of bleeding in major surgery in patients with moderate and severe hereditary Factor X deficiency.

Erenumab

Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the first and only FDA approved treatment specifically developed to prevent migraine by blocking the … Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines

Tocofibrate

The usage of the INN stem '-fibrate' in the name indicates that Tocofibrate is a clofibrate derivative, peroxisome proliferator activated receptor-a (PPAR-a) agonist. … Tocofibrate is a small molecule drug.